Abstract
Bupropion has been used to treat psychic depression and as a therapy for smoking cessation, the latter mainly in association with nicotine. However, there have been no detailed studies of the hemodynamic effects of the association of bupropion with nicotine during replacement therapy. In this study, we evaluated the effects of such an association on the cardiovascular parameters in anesthetized dogs. Bupropion, either alone or together with nicotine, had no significant effect on the cardiac index (Cl; 4.7±0.2 vs 4.3±0.1 and 3.5±0.3 vs 3.4±0.3 L.min−1.m2, respectively; mean±SEM) and mean arterial pressure (MAP; 134±5.0 vs 145±11.0 and 118±5.0 vs 133±10.5 mmHg, respectively). There was a slight but significant increase in the systemic vascular resistance index (SVRI; 2165±93 vs 2645±126 and 2335±100 vs 2737±200 dyn.cm−5m−2, respectively). However, there was a significant increase in the mean pulmonary artery pressure (MPAP; 20±0.8 vs 25±1.6 and 18±1.3 vs 25±1.6 mmHg, respectively; p<0.05) and pulmonary vascular resistance index (IRVP; 194±11 vs 272±21 and 206±32 vs 307±42 dyn.cm−5m−2, respectively; p<0.05). These results show that bupropion alone or in association with nicotine does not markedly affect most hemodynamic parameters of the systemic circulation, although the significant increase in MPAP and IRVP can elevate the pulmonary pressure.
Similar content being viewed by others
References
Jonas, M.A., Oates, J.A., Ockene, J.K., and Hennekens, C.H. (1992). Statement on smoking and cardiovascular disease for health care professionals. Circulation 86:1664–1669.
Jain, A. (2003). Treating nicotine addiction. Br. Med. J. 327:1394–1395.
Gold, P.B., Rubey, R.N., and Harvey, R.T. (2002). Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care. Am. J. Addict. 11:315–331.
Dalsgareth, O.J., Hansen, N.C., Soes-Petersen, U., et al. (2004). A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob. Res. 6:55–61.
Thomson, C.C. and Rigotti, N.A. (2003). Hospital- and clinic-based smoking cessation interventions for smokers with cardiovascular disease. Prog. Cardiovasc. Dis. 45: 459–479.
Tonstad, S. and Johnston, J.A. (2004). Does bupropion have advantages over other medical therapies in the cessation of smoking? Expert. Opin. Pharmacother. 5:727–734.
Jorenby, D.E., Leischow, S.J., Nides, M.A., et al. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340:685–691.
Paganelli, M.O., Tanus-Santos, J.E., Sabha, M., et al. (2006). Hemodynamic effects of bupropion in anesthetized dogs. Eur. J. Pharmacol. 530:124–127.
Hurt, R.D., Sachs, D.P., Glover, E.D., et al. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337:1195–1202.
Aubin, H.J., Lebargy, F., Berlin, I., Bidaut-Mazel, C., Chemali-Hudry, J., and Lagrue, G. (2004). Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 99:1206–1218.
Johnstone, E., Hey, K., Drury, M., et al. (2004). Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quitattempt. Addict. Biol. 9:227–232.
Tashkin, D.P., Kanner, R., Bailey, W., et al. (2001). Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet 357:1571–1575.
García-Río, F., Serrano, S., Mediano, O., Alonso, A., and Villamar, J. (2001). Safety profile of bupropion for chronic obstructive pulmonary disease. Lancet 358:1009–1010.
Swanson, N.A., Burroughs, C.C., Long, M.A., and Lee, R.W. (2003). Controlled trial for smoking cessation in a Navy shipboard population using nicotine patch, sustained-release buproprion, or both. Mil. Med. 168:830–834.
Cicardo, V.H., Mastronardi, I.O., Rondina, D.C., and Carbone, S.E. (1986). Bupropion. Effects on cerebral monoamines in rat and on blood pressure in dog. Gen. Pharmacol. 17:711–714.
Hida, W., Tun, Y., Kikuchi, Y., Okabe, S., and Shirato, K. (2002). Pulmonary hypertension in patients with chronic obstructive pulmonary disease: recent advances in pathophysiology and management. Respirology 7:3–13.
Cremers, B., Schmidt, K.I., Maack, C., Schafers, H.J., and Bohm, M. (2003). Catecholamine release in human heart by bupropion. Eur. J. Pharmacol 467:169–171.
Przyklenk, K. (1994). Nicotine exacerbates postischemic contractile dysfunction of ‘stunned” myocardium in the canine model. Circulation 89:1272–1281.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paganelli, M.O., Martins, L.C., Chaud, M.V. et al. Hemodynamic effects of a combination of bupropion and nicotine in anesthetized dogs. Cardiovasc Toxicol 6, 63–67 (2006). https://doi.org/10.1385/CT:6:1:63
Issue Date:
DOI: https://doi.org/10.1385/CT:6:1:63